Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program.

TitleEstimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program.
Publication TypeJournal Article
Year of Publication2023
AuthorsArbanas, JCave, Damberg, CL, Leng, M, Harawa, N, Sarkisian, CA, Landon, BE, Mafi, JN
JournalJAMA Internal Medicine
Volume183
Issue8
Pagination885-889
ISSN Number2168-6114
KeywordsHealth Care Costs, lecanemab, Medicare spending
Abstract

Lecanemab, an antidementia medication with modest clinical benefit, received accelerated US Food and Drug Administration (FDA) approval. Traditional FDA approval of lecanemab could occur in 2023, prompting Medicare to reconsider coverage restrictions and potentially enabling widespread use. Lecanemab’s $26 500 proposed annual acquisition cost and ancillary spending (eg, imaging) could increase Medicare spending, possibly leading to beneficiary premium increases. To estimate annual Medicare spending on lecanemab, we performed a cost analysis using nationally representative survey data from the 2018 Health and Retirement Study (HRS).

DOI10.1001/jamainternmed.2023.1749
Citation Key13066
PubMed ID37167598
PubMed Central IDPMC10176174